10-Q: Simulations Plus Reports Mixed Q2 Results: Revenue Up, But Profitability Declines Due to Acquisition Costs

Simulations Plus reports a 23% increase in revenue for the quarter ended February 28, 2025, but net income decreased due to higher costs associated with the Pro-ficiency acquisition.

Summary

• Simulations Plus reported a 23% increase in revenue for the three months ended February 28, 2025, reaching $22.4 million compared to $18.3 million in the same period last year.
• Software-related revenue increased by 16% to $13.5 million, while service-related revenue increased by 34% to $8.9 million.
• Cost of revenues increased significantly by 83% to $9.3 million, primarily due to higher amortization expenses related to the Pro-ficiency acquisition and increased service-related costs.
• Gross profit remained relatively flat at $13.1 million, with a gross margin of 59% compared to 72% in the prior year.
• Operating expenses increased by 19% to $10.4 million, driven by higher research and development and sales and marketing expenses.
• Net income decreased by 24% to $3.1 million, with earnings per share (EPS) dropping to $0.15 from $0.20.
• For the six months ended February 28, 2025, revenue increased by 26% to $41.4 million, but net income decreased by 45% to $3.3 million.
• The company's cash and cash equivalents stood at $11.0 million, with $10.4 million in short-term investments and working capital of $36.0 million as of February 28, 2025.
• The company completed the final payment of $1.6 million related to the holdback liability from the Immunetrics acquisition.
• The company reorganized its internal structure to create a more integrated operating platform based on key products and services offerings rather than separate divisions based on its prior acquisitions.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. Revenue growth is positive, but declining profitability due to acquisition costs and increased operating expenses tempers the overall sentiment. The company's strong cash position provides some reassurance.

Positives

• Revenue increased by 23% for the quarter and 26% for the six months ended February 28, 2025, indicating strong growth in both software and service segments.
• The company has $11.0 million in cash and cash equivalents and $10.4 million in short-term investments, providing a solid financial foundation.
• The completion of the final payment related to the Immunetrics acquisition removes a liability and simplifies the company's financial structure.
• The company's reorganization of its internal structure to create a more integrated operating platform based on key products and services offerings rather than separate divisions based on its prior acquisitions may lead to greater scientific collaboration and knowledge-sharing within the Company, leading to identifying new opportunities that both advance the Company's business objectives and deepen client relationships.

Negatives

• Net income decreased by 24% for the quarter and 45% for the six months ended February 28, 2025, primarily due to increased costs associated with the Pro-ficiency acquisition.
• The cost of revenues increased significantly by 83% for the quarter and 85% for the six months ended February 28, 2025, impacting profitability.
• Gross margin decreased from 72% to 59% for the quarter and from 70% to 56% for the six months ended February 28, 2025, indicating a decline in efficiency.
• Interest income decreased due to the use of cash from investment in debt securities to acquire Pro-ficiency.

Risks

• The integration of Pro-ficiency may not be successful, leading to lower-than-expected performance and potential adverse effects on the company's stock price.
• The company faces risks related to artificial intelligence and machine learning, including reputational harm, competitive harm, and legal and regulatory risks.
• Changes in government regulation, funding, or practices relating to the pharmaceutical or biotechnology industries could decrease the need for the company's services.
• Cash expenditures associated with the acquisition of Pro-ficiency may create certain liquidity and cash flow risks for the company.
• The company relies on government assistance in the form of cash grants, and the interruption or termination of these grants could have an adverse impact on the company's business.

Future Outlook

The company expects existing cash, cash equivalents, short-term investments, cash generated by ongoing operations, and working capital will be sufficient to fund operating activities and cash commitments for investing and financing activities and material capital expenditures for the next 12 months and beyond. The company continues to seek opportunities for strategic acquisitions, investments, and partnerships.

Industry Context

Simulations Plus operates in the highly competitive biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. The company's performance is affected by its ability to develop new products and find new distribution channels. The acquisition of Pro-ficiency expands Simulations Plus's reach across the drug development value chain, positioning it to compete more effectively in the market.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without specific industry benchmarks for companies with a similar mix of software and services in biosimulation and medical communications.
• However, companies like Certara also offer biosimulation software and services, and their financial performance could be used as a general point of reference.
• Other companies in the broader pharmaceutical services industry, such as Syneos Health or IQVIA, may provide some context for growth rates and profitability, although their business models are not directly comparable.
• The company's gross margin of 59% for the quarter is lower than some pure-play software companies but may be typical for companies with a significant services component.

Legal Proceedings

• The company is not a party to any legal proceedings and is not aware of any pending or threatened legal proceedings of any kind.

Stakeholder Impact

• Shareholders may be concerned about the decline in net income and EPS, but reassured by the revenue growth and strong cash position.
• Employees may experience changes as a result of the Pro-ficiency integration and the internal reorganization.
• Customers should benefit from the expanded capabilities and integrated platform resulting from the acquisition.
• Suppliers may see increased business opportunities as the company grows.

Next Steps

• The company will continue to focus on integrating Pro-ficiency and realizing synergies.
• The company will continue to seek opportunities for strategic acquisitions, investments, and partnerships.
• The company will monitor the evolving regulatory landscape related to AI and adapt its practices accordingly.

Key Dates

Keywords

Simulations Plus, financial results, revenue, net income, Pro-ficiency, acquisition, software, services, pharmaceutical, biosimulation